Navigation Links
Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 21st Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2009 at 9:00 a.m. EST (6:00 a.m. PST). The conference is being held at The New York Palace Hotel. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

The corporate presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through December 15, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended September 30, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

SOURCE Anadys Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
4. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
5. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
10. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a ... of innovative therapies based upon tetracycline chemistry, announced ... for the treatment of moderate to severe acne ... is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic ...
(Date:3/27/2017)... -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board ... as Impax,s President and Chief Executive Officer and a ... Mr. Bisaro will succeed J. Kevin Buchi , ... Officer since December of 2016. With ... Bisaro, 56, is an accomplished global business leader who ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. ... for life-threatening inherited liver diseases in children, today ... full year ended December 31, 2016 and provided ... "PhaseRx continued to make progress during the ... positive results from our non-human primate safety study, and ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis ... type of groin injury, it occurs when the muscles around the pelvis become ... and around the lower torso, as well as accompanying tenderness and weakness. Without ...
(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... ... , ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from ... time,” she said. , She thinks the coming week is going to be a very ... have to help my students.” , The award will allow the 4th grade teacher at ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently ... and require expert user knowledge. In a live webinar on April 11th and ... yet highly accurate, determination of sodium. , It has long been known that ...
Breaking Medicine News(10 mins):